

## Inpatient and Outpatient AntibioGram

Ascension Sacred Heart Bay

Date Disseminated: February 2025

Data are percent susceptible; first isolates only  
MRSA Rate: 45%

	Antimicrobial Susceptibility Report: January 2024 - December 2024																		Criteria for Use / Restricted Agents						
	No. of isolates	Amikacin <sup>a</sup>	Amoxicillin/Clavulanate	Ampicillin <sup>b</sup>	Ampicillin/Sulbactam	Cefazolin	Cefepime	Ceftriaxone	Cefuroxime / Cephalexin	Clindamycin	Doxycycline	Gentamicin <sup>a</sup>	Nitrofurantoin	Oxacillin / Nafcillin <sup>d</sup>	Piperacillin/Tazobactam	Sulfa/Trim (Bactrim)	Tetracycline	Tobramycin <sup>a</sup>	Ceftazidime	Ciprofloxacin <sup>f</sup>	Levofloxacin <sup>f</sup>	Linezolid	Meropenem	Vancomycin	
Gram-positive																									
Enterococcus faecalis	193		100	100	100						28		100		100		24	-		85	86	100*	-	98	
Enterococcus faecium	51		15	10	15						8		56*		15		15*	-		11*	11*	100	-	24	
Staphylococcus aureus <sup>f</sup>	367	-	55		55	40*	-	55	55	70	95	98	100*	55	55	93	89	-		60	63	100	-	100	
MRSA <sup>i</sup>	165	-									67	90	96	100*			89	85		-	28	31	100	-	100
MSSA <sup>i</sup>	203	-	100		100	100	-	100	100	73	100	99	100*	100	100	96	92	-		86	89	100*	-	100	
Staphylococcus epidermidis <sup>f</sup>	79	-	36		35	43*	-	35	35	53	85	94	100*	35	36	53	75	-		62	62	100	-	100	
Gram-negative																									
Enterobacter cloacae complex <sup>e</sup>	63	100					90	-	-		-	100	54*		75	90	-	-	75	100	97		100		
Escherichia coli	741	100	78	50	58	82 <sup>c</sup>	89	83	- <sup>c</sup>		-	91	95		93	70	71	83	91	65	65		100		
Klebsiella aerogenes <sup>e</sup>	32	100					97	72	-		-	97	14*		81	100	-	-	78	88	88		100*		
Klebsiella pneumoniae	264	100	86		74	84 <sup>c</sup>	87	83	- <sup>c</sup>		-	94	21		94	83	57*	93*	88	82	78		100		
Morganella morganii	32	100*					-	-	-		-	91			100	88	-	100*	88	81	81		100*		
Proteus mirabilis	119	100	100	86*	91	93 <sup>c</sup>	97	93	- <sup>c</sup>		-	92			98	85	-	86*	97	79	79		99		
Pseudomonas aeruginosa	175	99					93								89			100*	89	84	79		92		
Serratia marcescens	35	100					97	94	-		-	100			-	97	-	100*	97	88	86		100		

**NOTE:** Narrowest agent needed to cover pathogens suspected per evidence and individual patient history recommended; >80% susceptible is acceptable

<sup>a</sup>aminoglycosides should not be used as monotherapy except for in urinary source

<sup>b</sup>ampicillin results predict activity of amoxicillin, amoxicillin/clavulanate, ampicillin/sulbactam, and piperacillin/tazobactam for non-beta-lactamase producing enterococci. %S have not been tested for these isolates but have been included and match the ampicillin susceptibility result as appropriate

<sup>c</sup>reflects susceptibility of urine isolates only due to limitations of current antimicrobial susceptibility tests. cefazolin results when used for treatment of uncomplicated UTIs due to *E. coli*, *K. pneumoniae*, and *P. mirabilis*, can be used to predict results for oral agents cefdinir, cefuroxime, and cephalexin.

<sup>d</sup>oxacillin results for methicillin (oxacillin)-susceptible staphylococci can be applied to amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin/tazobactam, cefdinir, cephalexin, cefuroxime, cefazolin, cefepime, ceftriaxone, and meropenem. %S have not been tested for all these bug-drug combinations but have been included and match the oxacillin susceptibility results as appropriate

<sup>e</sup>*Enterobacter cloacae*, *Klebsiella aerogenes*, and *Citrobacter freundii* may develop resistance during prolonged therapy with 3rd-generation cephalosporins due to derepression of AmpC beta-lactamase. Isolates initially susceptible may become resistant within 3-4 days after initiation of therapy. If treatment is intended to be > 1 week, testing repeat isolates may be warranted if using 3rd-generation cephalosporins; otherwise use cefepime.

<sup>f</sup>Staphylococcus spp may develop resistance during prolonged therapy with quinolones. Isolates initially susceptible may become resistant within 3-4 days after initiation of therapy. Testing repeat isolates may be warranted or use of alternative narrower agent.

\*less than 30 isolates tested

Key:   intrinsically resistant or poor coverage  
  None or very few isolates tested  
  empiric drug of choice